T-Cell Lymphoma Clinical Trials 2022

Browse 17 T Cell Lymphoma Medical Studies Across 61 Cities
116 T Cell Lymphoma Clinics

Condition

Location

Distance

Age

Clinical Trials T-Cell Lymphoma Clinical Trials 2022

Reviewed by Michael Gill, B. Sc.

Photo of Memorial Sloan Kettering Cancer Center 1

Phase-Based Progress Estimates

Pharmacokineticsfor Lymphoma, Diffuse

The purpose of this study is to find out whether it is practical to use a newer way to calculate melphalan dose given (called population PK model) in BEAM chemotherapy before AHCT. Standard dose is fixed for everybody and is calculated using height and weight. The population PK model, tested in this study, uses information based on people who have previously received melphalan and aims to calculate an optimal dose separately for each person. Study researchers think that the dose calculated using the population PK model may still be effective but have less side effects than the standard melphalan dose.

Photo of washington 1

Phase-Based Progress Estimates

Tagraxofuspfor Lymphoma, B-Cell

Washington, United States

Waitlist Available

Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patients with relapsed/refractory hematologic malignancies. The mechanism by which tagraxofusp kills cells is distinct from that of conventional chemotherapy. Tagraxofusp directly targets CD123 that is present on tumor cells, but is expressed at lower or levels or absent on normal hematopoietic stem cells. Tagraxofusp also utilizes a payload that is not cell cycle dependent, making it effective against both highly proliferative tumor cells and also quiescent tumor cells. The rationale for clinical development of tagraxofusp for pediatric patients with hematologic malignancies is based on the ubiquitous and high expression of CD123 on many of these diseases, as well as the highly potent preclinical activity and robust clinical responsiveness in adults observed to date. This trial includes two parts: a monotherapy phase and a combination chemotherapy phase. This design will provide further monotherapy safety data and confirm the FDA approved pediatric dose, as well as provide safety data when combined with chemotherapy. The goal of this study is to improve survival rates in children and young adults with relapsed hematological malignancies, determine the recommended phase 2 dose (RP2D) of tagraxofusp given alone and in combination with chemotherapy, as well as to describe the toxicities, pharmacokinetics, and pharmacodynamic properties of tagraxofusp in pediatric patients. About 54 children and young adults will participate in this study. Patients with Down syndrome will be included in part 1 of the study.

Waitlist Available

Photo of florida 1

Phase-Based Progress Estimates

STP938for Lymphoma, T-Cell

The Phase 1 part of the study is a dose escalation of STP938 as monotherapy. The Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas.

Photo of New York 1

Phase-Based Progress Estimates

ONO-4685for Lymphoma, T-Cell

This study is evaluating whether a drug called ONO-4685 can help treat lymphoma.

Photo of Duarte 1

Phase-Based Progress Estimates

Quality-of-Life Assessmentfor Sezary Syndrome

FDA Approved Drug

This trial is studying the effect of combining two treatments, extracorporeal photopheresis and mogamulizumab, to treat erythrodermic cutaneous T cell lymphoma. Quality-of-Life Assessment is a treatment for Sezary Syndrome that has been approved by the FDA for a different condition. No patients in this trial will receive a placebo.

FDA Approved Drug

Photo of Boston 1

Phase-Based Progress Estimates

CAR-37 T Cellsfor Lymphoma, Diffuse

This trial is studying how well it works in treating people with relapsed or refractory CD37+ hematologic malignancies. CAR-37 T cells is used to treat Lymphoma, Diffuse and is free of charge. This treatment has previously been approved by the FDA for a different condition. No patients in this trial will receive a placebo.

Photo of university of michigan comprehensive cancer center 1

Phase-Based Progress Estimates

CPI-0209for Lymphoma, T-Cell

FDA Approved Drug

This trial is testing a new drug, CPI-0209, to see if it's safe and effective in treating patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor of EZH2. CPI-0209 is a treatment for lymphoma that will not be receiving a placebo. This treatment has been approved by the FDA for a different condition and is free.

FDA Approved Drug

Phase-Based Progress Estimates

ATLCAR.CD30 T Cellsfor Lymphoma, T-Cell

Winston-Salem, NC

FDA Approved Drug

This trial is testing a new treatment for lymphoma that involves modifying a patient's T cells so that they will attack the cancer. There are risks associated with the treatment and with the study procedures, but the hope is that this will be an effective treatment for those who have relapsed or are refractory to other treatments. The primary treatment being studied is ATLCAR.CD30 T cells, which is used to treat Lymphoma, T-Cell. This treatment has previously been approved by the FDA for a different condition. No patients in this trial will receive a placebo.

FDA Approved Drug

Photo of md university of maryland medical center 1

Phase-Based Progress Estimates

Brentuximab Vedotinfor Peripheral T-Cell Lymphoma

FDA Approved Drug

This trial will determine if brentuximab vedotin is effective and safe when used to re-treat patients whose cancer progressed after they stopped taking the drug. Brentuximab vedotin is used to treat Peripheral T-Cell Lymphoma. Brentuximab vedotin is a cancer medication that works by slowing or stopping the growth of cancer cells.

FDA Approved Drug

Photo of Columbus 1

Phase-Based Progress Estimates

Cabiralizumabfor Peripheral T-Cell Lymphoma

Waitlist Available

FDA Approved Drug

This trial is studying if the combination of nivolumab and cabiralizumab can help patients with relapsed or refractory peripheral T cell lymphoma. The drug cabiralizumab is being used to treat Peripheral T-Cell Lymphoma in this trial. This is not the first time that the drug has been approved by the FDA for use, as it has been approved for a different condition in the past. In this trial, there will be no patients receiving a placebo.

Waitlist Available

FDA Approved Drug

Photo of Chicago 1

Phase-Based Progress Estimates

IPH4102for Lymphoma, T-Cell

This trial is testing a new drug for people with Sezary Syndrome or Mycosis Fungoides. IPH4102 is a medication used to treat Lymphoma, T-Cell. This medication will not be given to any patients as a placebo.

Photo of the university of texas md anderson cancer center 1

Phase-Based Progress Estimates

CS1001for Lymphoma, T-Cell

Waitlist Available

This trial is testing a new drug to treat a type of cancer that has come back or does not respond to other treatments. This trial is testing CS1001, a potential treatment for Lymphoma, T-Cell. All patients in the trial will receive CS1001, and there is no placebo group.

Waitlist Available

Photo of Duarte 1

Phase-Based Progress Estimates

Nivolumab And EPOCHfor Lymphoma, T-Cell, Peripheral

Waitlist Available

FDA Approved Drug

This trial is testing if adding nivolumab to the standard of care chemotherapy can become the new first line treatment for a type of cancer called peripheral T cell lymphoma. Nivolumab and EPOCH is used to treat Lymphoma, T-Cell, Peripheral. This treatment is free for patients in the trial. Nivolumab and EPOCH has previously been approved by the FDA for a different condition. No patients in this trial will receive a placebo, which is common in clinical trials.

Waitlist Available

FDA Approved Drug

Photo of UPMC Hillman Cancer Center 1

Phase-Based Progress Estimates

Duvelisibfor Lymphoma

Waitlist Available

FDA Approved Drug

This trial is testing a new cancer drug for patients with a certain type of T cell lymphoma who have relapsed or who haven't responded to other treatments. The primary treatment in this trial is duvelisib, which is used to treat lymphoma. There is no placebo group in this trial; all patients will receive duvelisib. This drug has previously been approved by the FDA for a different condition.

Waitlist Available

FDA Approved Drug

Photo of ny memorial sloan-kettering cancer center 1

Phase-Based Progress Estimates

Lenalidomidefor Sezary Syndrome

FDA Approved Drug

This trial is testing durvalumab with or without lenalidomide to treat patients with cutaneous or peripheral T cell lymphoma that has come back and does not respond to treatment. Lenalidomide is used as the primary treatment for Sezary Syndrome in this trial. It has been approved by the FDA for a different condition in the past. There will be no placebo group in this trial, and the treatment is free for patients.

FDA Approved Drug

Photo of Cleveland 1

Phase-Based Progress Estimates

Brentuximab Vedotinfor Lymphoma

FDA Approved Drug

This trial will study the use of Brentuximab Vedotin in patients with mature T-cell lymphoma who have been treated with at least one type of chemotherapy, but are not responding or the cancer has come back after the previous treatment. Brentuximab vedotin is used to treat Lymphoma. Brentuximab vedotin was previously approved by the FDA for a different condition. This trial will not include a placebo group.

FDA Approved Drug

Photo of california 1

Phase-Based Progress Estimates

Anti-thymocyte Globulinfor Granulomatous Slack Skin

Waitlist Available

FDA Approved Drug

This trial will use a non-myeloablative approach to allogeneic transplantation to treat patients with advanced MF/SS. This is a reasonable option given the median age at diagnosis and the increased risk of infection for these patients. The primary treatment being studied is anti-thymocyte globulin, and it is being used to treat Granulomatous Slack Skin. There is no placebo group in this trial. This treatment has previously been approved by the FDA for a different condition.

Waitlist Available

FDA Approved Drug

17 T Cell Lymphoma Clinical Trials Near Me

New York, NY

Washington, United States

Portland, OR

Houston, TX

More Trial Locations

An interactive map to display trial locations for Memorial Sloan Kettering Cancer Center, Children's National Medical Center, Oregon Health & Science University, Texas Children's Hospital/Baylor College of Medicine, and 103 more locations.

Most Popular References for T Cell Lymphoma Clinical Trials

Frequency

Citation

19

Valipour A, Jäger M, Wu P, Schmitt J, Bunch C, Weberschock T. Interventions for mycosis fungoides. Cochrane Database Syst Rev. 2020 Jul 7;7:CD008946. doi: 10.1002/14651858.CD008946.pub3.

1

Weng, Wen-Kai, Randall Armstrong, Sally Arai, Cindy Desmarais, Richard Hoppe, and Youn H. Kim. 2013. “Minimal Residual Disease Monitoring with High-throughput Sequencing of T Cell Receptors in Cutaneous T Cell Lymphoma”. Science Translational Medicine. American Association for the Advancement of Science (AAAS). doi:10.1126/scitranslmed.3007420.

1

Scarfò, Irene, Maria Ormhøj, Matthew J. Frigault, Ana P. Castano, Selena Lorrey, Amanda A. Bouffard, Alexandria van Scoyk, et al.. 2018. “Anti-cd37 Chimeric Antigen Receptor T Cells Are Active Against B- and T-cell Lymphomas”. Blood. American Society of Hematology. doi:10.1182/blood-2018-04-842708.

1

Weng, Wen-Kai, Sally Arai, Andrew Rezvani, Laura Johnston, Robert Lowsky, David Miklos, Judith Shizuru, et al.. 2020. “Nonmyeloablative Allogeneic Transplantation Achieves Clinical and Molecular Remission in Cutaneous T-cell Lymphoma”. Blood Advances. American Society of Hematology. doi:10.1182/bloodadvances.2020001627.

Top Hospitals for T Cell Lymphoma Clinical Trials

Location

Active T Cell Lymphoma Clinical Trials

All Time Trials for T Cell Lymphoma

First Recorded T Cell Lymphoma Trial

Trials

Memorial Sloan Kettering Cancer Center, New York, New York

2

23

2005

Pharmacokinetics for Lymphoma, Diffuse

, Duvelisib for Lymphoma

Oregon Health & Science University, Portland, Oregon

2

5

2015

Tagraxofusp for Lymphoma, B-Cell

, ONO-4685 for Lymphoma, T-Cell

Dana-Farber Cancer Institute, Boston, Massachusetts

2

16

2005

Tagraxofusp for Lymphoma, B-Cell

, IPH4102 for Lymphoma, T-Cell

Memorial Sloan-Kettering Cancer Center, New York, New York

2

15

2001

ONO-4685 for Lymphoma, T-Cell

, Lenalidomide for Sezary Syndrome

University of Alabama at Birmingham, Birmingham, Alabama

2

9

2008

ONO-4685 for Lymphoma, T-Cell

, IPH4102 for Lymphoma, T-Cell

Top Treatments for T Cell Lymphoma Clinical Trials

Treatment Name

Active T Cell Lymphoma Clinical Trials

All Time Trials for T Cell Lymphoma

First Recorded T Cell Lymphoma Trial

Trials

Pharmacokinetics

1

1

2022

Pharmacokinetics for Lymphoma, Diffuse

Tagraxofusp

1

1

2022

Tagraxofusp for Lymphoma, B-Cell

STP938

1

1

2022

STP938 for Lymphoma, T-Cell

ONO-4685

1

1

2021

ONO-4685 for Lymphoma, T-Cell

Quality-of-Life Assessment

1

5

2016

Quality-of-Life Assessment for Sezary Syndrome

Top Cities for T Cell Lymphoma Clinical Trials

City

Active T Cell Lymphoma Clinical Trials

Top Active Site for T Cell Lymphoma Clinical Trials

Trial List

New York, New York

8

Memorial Sloan Kettering Cancer Center

Pharmacokinetics for Lymphoma, Diffuse

, Tagraxofusp for Lymphoma, B-Cell

, ONO-4685 for Lymphoma, T-Cell ... View More

Boston, Massachusetts

6

Dana-Farber Cancer Institute

Tagraxofusp for Lymphoma, B-Cell

, CAR-37 T cells for Lymphoma, Diffuse

, CPI-0209 for Lymphoma, T-Cell ... View More

Houston, Texas

5

Texas Children's Hospital/Baylor College of Medicine

Tagraxofusp for Lymphoma, B-Cell

, ONO-4685 for Lymphoma, T-Cell

, IPH4102 for Lymphoma, T-Cell ... View More

Philadelphia, Pennsylvania

5

Thomas Jefferson University

Tagraxofusp for Lymphoma, B-Cell

, IPH4102 for Lymphoma, T-Cell

, IPH4102 for Lymphoma, T-Cell ... View More

Baltimore, Maryland

4

University of Maryland

Tagraxofusp for Lymphoma, B-Cell

, CPI-0209 for Lymphoma, T-Cell

, brentuximab vedotin for Peripheral T-Cell Lymphoma ... View More

Which phases are most popular for t-cell lymphoma clinical trials?

Phase

Active T Cell Lymphoma Clinical Trials

Number of Unique Treatments

Number of Active Locations

Trial List

Phase 1

3

3

11

Tagraxofusp for Lymphoma, B-Cell

, ONO-4685 for Lymphoma, T-Cell

, CAR-37 T cells for Lymphoma, Diffuse

Phase 1 & 2

4

4

20

STP938 for Lymphoma, T-Cell

, CPI-0209 for Lymphoma, T-Cell

, Nivolumab and EPOCH for Lymphoma, T-Cell, Peripheral ... View More

Phase 2

9

9

50

Quality-of-Life Assessment for Sezary Syndrome

, ATLCAR.CD30 T cells for Lymphoma, T-Cell

, brentuximab vedotin for Peripheral T-Cell Lymphoma ... View More

N/A

1

1

1

Pharmacokinetics for Lymphoma, Diffuse

How many t-cell lymphoma clinical trials are open to youth and / or seniors?

Age Group

Active T Cell Lymphoma Clinical Trials

Trial List

18+

16

Pharmacokinetics for Lymphoma, Diffuse

, STP938 for Lymphoma, T-Cell

, ONO-4685 for Lymphoma, T-Cell ... View More

< 65

1

Tagraxofusp for Lymphoma, B-Cell

Most Recent T Cell Lymphoma Clinical Trials

Clinical Trial

Began Recruiting Date

Phase

Pharmacokinetics for Lymphoma, Diffuse

9/9/2022

N/A

STP938 for Lymphoma, T-Cell

8/3/2022

Phase 1 & 2

Tagraxofusp for Lymphoma, B-Cell

8/1/2022

Phase 1

ONO-4685 for Lymphoma, T-Cell

12/10/2021

Phase 1

CAR-37 T cells for Lymphoma, Diffuse

6/19/2020

Phase 1

Pediatric T Cell Lymphoma Clinical Trials

Clinical Trial

Began Recruiting Date

Phase

Tagraxofusp for Lymphoma, B-Cell

8/1/2022

Phase 1

Senior Friendly T Cell Lymphoma Clinical Trials

Clinical Trial

Began Recruiting Date

Phase

Pharmacokinetics for Lymphoma, Diffuse

9/9/2022

N/A

STP938 for Lymphoma, T-Cell

8/3/2022

Phase 1 & 2

ONO-4685 for Lymphoma, T-Cell

12/10/2021

Phase 1

CAR-37 T cells for Lymphoma, Diffuse

6/19/2020

Phase 1

brentuximab vedotin for Peripheral T-Cell Lymphoma

10/28/2019

Phase 2

Recently Completed Studies with FDA Approved Treatments for T Cell Lymphoma

Treatment

Year

Mechanism of Action

Sponsor

Active T Cell Lymphoma Clinical Trials

rhIL-15

2019

National Cancer Institute (NCI)

0

Anti-CD30-CAR T cells

2017

National Cancer Institute (NCI)

0

About The Author

Michael Gill - B. Sc.

First Published: October 21st, 2021

Last Reviewed: September 15th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Back to top

Terms of Service